NCT02796950View on ClinicalTrials.gov

The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

January 20, 2017

Study Completion Date

January 20, 2017

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Acipimox

P.o. administration of 250 mg acipimox

Trial Locations (1)

8000

University Hospital of Aarhus, Aarhus

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT02796950 - The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion | Biotech Hunter | Biotech Hunter